Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Shares Outstanding (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Shares Outstanding for 4 consecutive years, with $44.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Shares Outstanding rose 14.63% to $44.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $44.8 million, a 14.63% increase, with the full-year FY2024 number at $44.8 million, up 14.63% from a year prior.
  • Shares Outstanding was $44.8 million for Q4 2024 at Werewolf Therapeutics, up from $43.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $44.8 million in Q4 2024 to a low of $1.8 million in Q1 2021.
  • A 4-year average of $31.2 million and a median of $31.1 million in 2022 define the central range for Shares Outstanding.
  • Biggest YoY gain for Shares Outstanding was 1471.25% in 2022; the steepest drop was 3.22% in 2022.
  • Werewolf Therapeutics' Shares Outstanding stood at $27.6 million in 2021, then increased by 14.15% to $31.5 million in 2022, then grew by 24.09% to $39.1 million in 2023, then increased by 14.63% to $44.8 million in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Shares Outstanding are $44.8 million (Q4 2024), $43.3 million (Q1 2024), and $39.1 million (Q4 2023).